Novo on haastanut Eli Lillyn oikeuteen harhaanjohtavaksi katsomastaan laihdutuslääkemainonnasta. Siinä Lilly vertaa Zepboundia Wegovyn vanhempaan ja miedompaan annokseen, vaikka Novolla on jo uudempi sekä tehokkaampi versio. Lilly korostaakin vertailunsa perustuvan ainoaan suoraan tutkimukseen.
Key Points
- Novo Nordisk CEO Mike Doustdar defended the drugmaker’s decision to sue rival Eli Lilly over its weight-loss drug advertising.
- “I am a big fan of competition. I think competition has to be fierce, but I also think competition has to be fair,” Doustdar said on CNBC’s “Mad Money.” “I believe that patients deserve to know the full truth together with their physicians before they make a choice of what product to take.”
https://www.cnbc.com/2026/08/12/novo-nordisk-ceo-defends-lawsuit-against-eli-lilly.html